AUP-16: More cost-effective than the current Standard Of Care at healing Diabetic Foot Ulcers revealed at ISPOR Europe 2023
Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company developing bacteria-based multi-target cell and gene therapies for chronic wounds and cancer, participated in ISPOR Europe Health Economics and Market Access conference held from 12-15 November in Copenhagen, Denmark. During this conference, Laurent Décory, COO of Aurealis Therapeutics, presented one of the company’s latest developments: a detailed […]
Aurealis Therapeutics launches Venous Leg Ulcer (VLU) scientific expert group, an important step towards AUP-16 VLU phase 2 clinical trial
Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company developing bacteria-based multi-target cell and gene therapies for chronic wounds and cancer, announces the initiation of its Venous Leg Ulcer (VLU) scientific expert group. This initiative is an important step towards the planning and execution of the Phase 2 clinical trial of AUP-16 for Venous Leg Ulcers […]
Aurealis Therapeutics announces first patient dosed in DIAMEND Phase 2 Diabetic Foot Ulcer clinical trial of AUP-16
Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company developing bacteria-based multi-target cell and gene therapies for chronic wounds and cancer, announced today that the first diabetic foot ulcer (DFU) patient has been successfully dosed in its DIAMEND phase 2 clinical study of AUP-16. This is a multi-center, single-blinded, randomized, standard-of-care plus placebo-controlled clinical trial that […]
Aurealis Therapeutics presented advancements in multi-target bacterial gene therapies at the 14th International Symposium on Lactic Acid Bacteria
Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company developing bacteria-based multi-target cell and gene therapies for chronic wounds and cancer, is making remarkable advances in the field with its 4-in-1 technology platform. Director of Genetic Engineering & Manufacturing, Igor Mierau, showcased the company’s research and results at the 14th International Symposium on Lactic Acid Bacteria, held […]
Aurealis Therapeutics shines in Nordic Life Science News with in-depth interview on gene therapy innovations
Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company creating bacteria-based multi-factor cell and gene therapies for chronic wounds and cancer, is excited to share its recent feature in the well-known life science journal, Nordic Life Science News. The article titled “From Theory to Therapy: Gene Therapy” has shared remarkable insights from an interview with Laurent Décory, COO […]
Aurealis Therapeutics strengthens its Board of Directors by appointing Jean de Gunzburg as a new member
Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company creating bacteria-based multi-factor cell and gene therapies for chronic wounds and cancer, announced today that Jean de Gunzburg, Scientist and Investor, Founder and Chairman of Zagdanut Ltd, Director of Cardiawave SA, previously CSO and Director of Da Volterra, and Founder and Chairman of Metsya Ltd, has been […]
Aurealis Therapeutics accelerates oncology program: First abstract published at ASCO as the team prepares for Annual Meeting in Chicago
Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for unmet medical needs, accelerates its expansion in Oncology with its first-in-class four-in-one Bacterial Cell and Gene Therapy AUP-55. The company’s first abstract, Effect of multi-targeting bacterial gene therapy on tumor regression and survival in mouse models of ovarian and intraperitoneal cancer, has […]
Aurealis Therapeutics announces approval of multi-center, randomized, placebo-controlled diabetic foot ulcer Phase 2 study to start May 2023 in Italy, Germany and Poland.
Aurealis Therapeutics, a Swiss-Finnish private clinical-stage synthetic biology company focusing on the development of lactic acid bacteria -based GMO cell and gene therapies, announces clinical trial application (CTA) approval of a multi-center, randomized, placebo-controlled diabetic foot ulcer (DFU) Phase 2 study to start this month in Italy, Germany, and Poland. The Global Coordinating Investigator of […]
Aurealis Therapeutics will be presenting during the European Wound Management Association (EWMA) 2023 Conference
Aurealis Therapeutics is excited to sponsor the European Wound Management Association (EWMA) 2023 Conference taking place in Milan, Italy from 3-5 May 2023. Our CEO Juha Yrjänheikki, COO Laurent Décory, and CMO Haritha Samaranayake and will be attending the conference. We will actively participate several parts of the event: On the 4th of May, Laurent Décory, COO […]
Aurealis Therapeutics is attending the Swiss Biotech Day 2023
Juha Yrjänheikki (CEO) and Laurent Décory (COO) will be attending the Swiss Biotech Day 2023 which will take place from 24-25 April in Basel, Switzerland. This will be a fantastic opportunity to meet investors and discuss potential partnerships with pharma companies. The Swiss Biotech Day is one of the leading biotechnology conferences in Europe offering […]
